Branded Pharma M&A Signal Engine

🔴 HIGH Alerts

Z-score ≥ 2.0

🟡 Elevated

Z-score 1.5–2.0

Companies Analyzed

Earnings transcripts

⚠️ FDA Flags

Compliance signals

🎯 Top M&A Prob

67%

MRK

Signal Distribution

M&A Probability Distribution

Alert Level Breakdown

Deal Type Mix

Acquirer vs Target Z-Score (bubble size = M&A probability)

All Companies — Enhanced M&A Signal Summary

Ticker	Signal	Alert	M&A Prob %	Deal Type	Acq. Score	Tgt. Score	CEO	Activist	Dry Powder	Top Phrases
MRKPATENT CLIFF Merck & Co	TARGET	🔴 HIGH	67%	Acquisition Target	61	95	⚪		$14.6B	loebusiness developmentloss of exclusivitybiosimilar competition
PFEPATENT CLIFF Pfizer	BOTH	🔴 HIGH	67%	Acquisition Target	66	144	⚪	⚠️	$1.1B	loebusiness developmentgeneric entryloss of exclusivity
BIIBPATENT CLIFF Biogen	ACQUIRER	🔴 HIGH	65%	Strategic Acquirer	51	16	🟡	⚠️	$3.0B	business developmentbiosimilar competitioncapital deploymentdeployment of capital
PTCTPATENT CLIFF PTC Therapeutics	BOTH	🔴 HIGH	58%	Acquisition Target	37	116	⚪		—	divestituretransformationtuck-in acquisitiontuck-in
ABBVPATENT CLIFF AbbVie	BOTH	🔴 HIGH	55%	Merger of Equals Candidate	36	119	🟡		$5.2B	loebiosimilar competitionbusiness developmentloss of exclusivity
RXRX Recursion Pharmaceuticals	TARGET	🔴 HIGH	54%	Acquisition Target	0	17	⚪		—	unlock valuetransformation
BMYPATENT CLIFF Bristol-Myers Squibb	TARGET	🟡 ELEVATED	52%	Merger of Equals Candidate	52	86	🟡		$10.2B	business developmentloegeneric entrypatent expiration
GILDPATENT CLIFF Gilead Sciences	BOTH	🔴 HIGH	50%	Merger of Equals Candidate	25	42	⚪		$7.6B	loebusiness developmentloss of exclusivitylicensing deal
SAGE Sage Therapeutics	TARGET	🔴 HIGH	49%	Strategic Monitor	6	14	⚪		—	strategic alternativescollaboration agreementrestructuring
JNJ Johnson & Johnson	MONITOR	⚪ NORMAL	48%	Strategic Monitor	7	35	⚪		$19.7B	separationtransformationrobust pipelineportfolio optimization
VRTX Vertex Pharmaceuticals	ACQUIRER	🟢 WATCH	42%	Strategic Monitor	11	0	⚪		$5.1B	business developmentcapital deployment
RGENPATENT CLIFF Repligen Corporation	BOTH	🔴 HIGH	42%	Merger of Equals Candidate	7	88	⚪		—	loerobust pipeline
FOLD Amicus Therapeutics	MONITOR	⚪ NORMAL	42%	Strategic Monitor	8	11	⚪	⚠️	$0.2B	ip protectionrestructuringgeographic expansionadjacencies
AMGNPATENT CLIFF Amgen	TARGET	🟡 ELEVATED	41%	Strategic Monitor	25	18	⚪		$9.1B	biosimilar competitionbusiness developmentrobust pipeline
ALNY Alnylam Pharmaceuticals	MONITOR	🟡 ELEVATED	41%	Strategic Monitor	4	0	⚪		$1.7B	global commercial
ROIV Roivant Sciences	TARGET	🟢 WATCH	41%	Strategic Monitor	18	17	⚪		—	transformationpipeline expansionbusiness developmentseparation
REGN Regeneron	MONITOR	⚪ NORMAL	41%	Strategic Monitor	17	0	⚪		$3.1B	business developmentcapital deployment
IONS Ionis Pharmaceuticals	MONITOR	⚪ NORMAL	41%	Strategic Monitor	5	3	⚪		$0.4B	commercial infrastructuretransformation
LLY Eli Lilly	ACQUIRER	🟢 WATCH	39%	Strategic Monitor	37	0	⚪		$7.2B	business developmentrobust pipeline
HALOPATENT CLIFF Halozyme Therapeutics	MONITOR	⚪ NORMAL	39%	Strategic Monitor	10	10	⚪		$0.1B	loss of exclusivitystrategic acquisitiongeographic expansion
EXEL Exelixis	MONITOR	⚪ NORMAL	39%	Strategic Monitor	17	14	⚪		$0.5B	business developmentrestructuringtransformationfragmented market
ARGX argenx	MONITOR	⚪ NORMAL	39%	Strategic Monitor	6	3	⚪		$3.5B	collaboration agreementtransformation
INCYPATENT CLIFF Incyte Corporation	MONITOR	⚪ NORMAL	38%	Strategic Monitor	0	13	⚪		$3.1B	loeseparation
PRTA Prothena	BOTH	🟢 WATCH	38%	Strategic Monitor	14	19	⚪		—	separationtransformationwell-capitalizedcommercial infrastructure
UTHR United Therapeutics	MONITOR	⚪ NORMAL	38%	Strategic Monitor	6	0	⚪		$1.6B	dry powder
MRNA Moderna	MONITOR	⚪ NORMAL	37%	Strategic Monitor	4	28	⚪		$2.6B	cost reductiongeographic expansion
ACAD ACADIA Pharmaceuticals	MONITOR	⚪ NORMAL	37%	Strategic Monitor	6	0	🟡		$0.2B	business development
IOVA Iovance Biotherapeutics	ACQUIRER	🟢 WATCH	35%	Strategic Monitor	11	0	⚪		—	robust pipelineglobal commercial
KYMR Kymera Therapeutics	MONITOR	⚪ NORMAL	35%	Strategic Monitor	5	0	⚪		—	well-capitalized
AUPH Aurinia Pharmaceuticals	MONITOR	⚪ NORMAL	34%	Strategic Monitor	0	20	⚪		—	restructuring
ARQT Arcutis Biotherapeutics	MONITOR	🟢 WATCH	34%	Strategic Monitor	0	0	🟡		—
SPRY ProSomnus	MONITOR	⚪ NORMAL	33%	Strategic Monitor	5	0	⚪		—	commercial infrastructure
GRFS Grifols	MONITOR	🟢 WATCH	31%	Strategic Monitor	0	10	⚪		—	portfolio optimizationrestructuring
JAZZ Jazz Pharmaceuticals	MONITOR	🟢 WATCH	31%	Strategic Monitor	13	0	⚪		—	licensing dealbusiness development
NKTR Nektar Therapeutics	MONITOR	🔴 HIGH	30%	Strategic Monitor	0	0	⚪		—

🎯 Deal Watch Next 180 Days

Highest-conviction pre-announcement M&A signals

PFEPfizer82TARGET🔴 HIGH0-90 days

Starboard Value activist engagement confirmed — CEO Bourla met with Starboard on turnaround pitch
Eliquis EU LOE May 2026, Ibrance generic erosion accelerating — LOE mentioned 9x in Q4 2025 transcript (all-time high)
Divestiture + single-asset language appearing in earnings calls — asset disposals signaled
Options FLAGGED: max single-strike vol 16,793, total vol 31,130 — elevated institutional positioning
Business development language 7x in transcript — simultaneously exploring acquirer/target deals

📋 Eliquis (apixaban) EU patent May 2026, US 2028. Ibrance (palbociclib) generics accelerating 2025-2026. Xeljanz generics 2025.
📅 Eliquis EU patent expiry May 2026 — 15.2% sales decline forecast. Q1 2026 earnings (April) — watch for strategic language shift or divestiture announcement.
🎯 JNJ, AMGN, AZN, SNY

SAGESage Therapeutics78TARGET🔴 HIGH0-90 days

REJECTED Biogen's offer to buy remaining stake — strongest deal indicator in entire universe
Strategic alternatives language 2x in Q1 2025 transcript (Tier 1 target phrase, z=5.1)
Biogen already owns significant stake from prior collaboration — natural acquirer
Restructuring language appearing — cost-cutting mode signals openness to deal
Small cap with no revenue moat — classic takeout candidate at right price

📋 N/A — pre-revenue/early commercial stage
📅 Biogen revised offer or competing bid. Board response to strategic alternatives review. Any data readout on remaining pipeline assets.
🎯 BIIB, JNJ, ABBV, PFE

MRKMerck & Co74ACQUIRER🔴 HIGH0-90 days

Creating SEPARATE cancer division — pre-spin or structural deal preparation for Keytruda LOE
Acquired Cidara Therapeutics for $9.2B (Nov 2025) — deal machine in active acquisition mode
Keytruda LOE 2028 — $25B+ revenue at risk, MUST acquire replacement revenue pipeline
LOE mentioned 7x + loss of exclusivity 2x + biosimilar competition in Q4 transcript (z=5.74)
Options FLAGGED: ratio 0.449, max single-strike vol 15,450 — heavy institutional call buying

📋 Keytruda (pembrolizumab) US LOE 2028. Januvia/Janumet generics ongoing. Gardasil competitive pressure.
📅 Expect 1-2 more large acquisitions ($5-15B range) in next 180 days. Cancer division spin timing. Q1 2026 earnings — acquisition announcement likely.

PTCTPTC Therapeutics63TARGET🟡 MEDIUM90-180 days

Divestiture mentioned 12x in Q4 2025 transcript — highest divestiture density in entire universe
Transformation language 8x — management actively reshaping portfolio
LOE detected — loss of exclusivity phrases appearing for first time
Target z-score 10.01 — massive spike, all-time high vs baseline
Tuck-in acquisition language simultaneously appearing — dual signal (buying/selling assets)

📋 Translarna (ataluren) EU authorization expired/under review. DMD franchise faces competitive pressure.
📅 Asset divestiture announcement. Portfolio restructuring completion. Q1 2026 earnings for strategic update.
🎯 RHHBY, NVS, SNY, VRTX